Cetera Investment Advisers lifted its position in shares of Amdocs Limited (NASDAQ:DOX - Free Report) by 17.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 61,640 shares of the technology company's stock after purchasing an additional 9,072 shares during the quarter. Cetera Investment Advisers owned about 0.05% of Amdocs worth $5,640,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently made changes to their positions in the company. OneDigital Investment Advisors LLC increased its position in Amdocs by 20.8% during the first quarter. OneDigital Investment Advisors LLC now owns 3,026 shares of the technology company's stock valued at $277,000 after acquiring an additional 521 shares during the last quarter. Farther Finance Advisors LLC increased its position in Amdocs by 17.5% during the first quarter. Farther Finance Advisors LLC now owns 988 shares of the technology company's stock valued at $90,000 after acquiring an additional 147 shares during the last quarter. Cambridge Investment Research Advisors Inc. increased its position in Amdocs by 7.8% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 6,738 shares of the technology company's stock valued at $616,000 after acquiring an additional 490 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Amdocs by 55.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 586 shares of the technology company's stock valued at $50,000 after purchasing an additional 208 shares during the period. Finally, Vanguard Group Inc. increased its position in Amdocs by 16.1% in the fourth quarter. Vanguard Group Inc. now owns 3,074,424 shares of the technology company's stock worth $261,756,000 after buying an additional 426,035 shares in the last quarter. 92.02% of the stock is currently owned by institutional investors.
Amdocs Price Performance
Amdocs stock traded up $1.19 during midday trading on Monday, reaching $85.68. 988,921 shares of the stock traded hands, compared to its average volume of 698,983. The stock's fifty day moving average is $90.67 and its 200-day moving average is $88.71. Amdocs Limited has a 12 month low of $78.61 and a 12 month high of $95.41. The stock has a market cap of $9.67 billion, a P/E ratio of 18.04, a PEG ratio of 1.40 and a beta of 0.51. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.21.
Amdocs (NASDAQ:DOX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The technology company reported $1.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.07. The business had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.12 billion. Amdocs had a return on equity of 19.52% and a net margin of 11.39%. The company's revenue for the quarter was down 9.4% on a year-over-year basis. During the same period last year, the company earned $1.56 EPS. As a group, equities research analysts anticipate that Amdocs Limited will post 6.21 EPS for the current year.
Amdocs Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Friday, July 25th. Stockholders of record on Monday, June 30th were issued a $0.527 dividend. This represents a $2.11 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, June 30th. Amdocs's dividend payout ratio is presently 44.42%.
Analysts Set New Price Targets
Several research firms recently issued reports on DOX. Wolfe Research began coverage on shares of Amdocs in a report on Tuesday, July 8th. They issued an "outperform" rating for the company. Wall Street Zen lowered shares of Amdocs from a "buy" rating to a "hold" rating in a report on Saturday. One analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Amdocs has a consensus rating of "Moderate Buy" and a consensus target price of $105.33.
Check Out Our Latest Research Report on Amdocs
Amdocs Company Profile
(
Free Report)
Amdocs Limited, through its subsidiaries, provides software and services worldwide. It designs, develops, operates, implements, supports, and markets open and modular cloud portfolio. The company provides CES23, a 5G and cloud-native microservices-based market-leading customer experience suite, that enables service providers to build, deliver, and monetize advanced services; Amdocs Subscription Marketplace, a software-as-a-service-based platform that includes an expansive network of pre-integrated digital services, such as media, gaming, eLearning, sports, and retail to security and business services; the monetization suite for charging, billing, policy, and revenue management; Intelligent networking suite with a set of modular, flexible, and open service lifecycle management capabilities for network automation journeys; amAIz, a telco GenAI framework; Amdocs Digital Brands Suite, a pre-integrated digital business suite; and Amdocs eSIM Cloud for service providers.
See Also

Before you consider Amdocs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amdocs wasn't on the list.
While Amdocs currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.